Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 4Interventional 1

Sponsor

Cancer Type

CNS 26Breast 10Thoracic 4Other solid neoplasm 3Lymphoid 3Sarcoma 2Other hematologic neoplasm 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1Gastrointestinal 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mental Status and Dementia Tests × Tumor-Agnostic × Clear all
NCT03052868 2017-02-14

Analysis of Neurocognitive Elements of Attention After Chemotherapy

University of Texas Southwestern Medical Center

Phase NA Completed
75 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡